Almost five years have elapsed since the introduction of latanoprost on several markets and considering the large number of publications dealing with it, the authors felt that it was worth re-evaluating the drug.
Methods
The criterion used to select trials for inclusion in the review was: all articles mentioning the drug in common electronic data-bases; these were then screened and considered, on the basis of methodological quality.
Results
Experimental data suggest that latanoprost acts by remodeling the extracellular matrix in the ciliary muscle, thus increasing the flow of aqueous humor through the ciliary muscle bundles of the uveoscleral pathway.
POAG
Latanoprost persistently improves the pulsatile ocular blood flow in primary open angle glaucoma (POAG). Recent trials confirmed the greater IOP-lowering efficacy of latanoprost vs. timolol, dorzolamide, brimonidine and unoprostone. Trials lasting up to 24 months showed that latanoprost is effective in long-term treatment of POAG and ocular hypertension (OH), with no signs of loss of efficacy when compared to timolol or dorzolamide. Latanoprost provides better control of circadian IOP. Non-responders to b-blockers should preferably be switched to latanoprost monotherapy before a combination therapy is started. The possibility of a fixed combination of latanoprost and timolol has been explored, with promising results.
NTG
Latanoprost is effective in normal tension glaucoma (NTG), lowering IOP, improving pulsatile ocular blood flow and increasing ocular perfusion pressure.
Other Glaucomas
Latanoprost may provide effective IOP control in angle-closure glaucoma after iridectomy, in pigmentary glaucoma, glaucoma after cataract extraction and steroid-induced glaucoma. However, latanoprost was effective in only a minority of pediatric cases of glaucoma and is contraindicated in all forms of uveitic glaucoma.
Safety
In the articles reviewed, new or duration-related adverse events were reported.
QuigleyH.A.. Number of people with glaucoma worldwide.Br J Ophthalmol1996; 80: 389–93.
2.
ThyleforsB.NegrelA.D.. The global impact of glaucoma.Bull World Health Organ1994; 72: 323–6.
3.
WensorM.D.McCartyC.A.StanislavskyY.L.LivingstonP.M.TaylorH.R.. The prevalence of glaucoma in the Melbourne visual impairment project.Ophthalmology1998; 105: 733–9.
4.
DamjiK.F.. Advances in molecular genetics of glaucoma: A perspective for the clinician.Semin Ophthalmol1999; 14: 171–9.
5.
CamrasC.B.AlmA.. Initial clinical studies with prostaglandins and their analogues.Surv Ophthalmol1997; 41(Suppl): S61–8.
6.
SjoquistB.JohanssonA.StjernschantzJ.. Pharmacokinetics of latanoprost in the cynomolgus monkey. 3rd communication: tissue distribution after topical administration on the eye studied by whole body autoradiography. Glaucoma Research Laboratories.Arzneimittelforschung1999; 49: 240–9.
7.
SjoquistB.TajallaeiS.StjernschantzJ.. Pharmacokinetics of latanoprost in the cynomolgus monkey. 1st communication: single intravenous, oral or topical administration on the eye.Arzneimittelforschung1999; 49: 225–33.
8.
SjoquistB.UhlinA.BydingP.StjernschantzJ.. Pharmacokinetics of latanoprost in the cynomolgus monkey. 2nd communication: repeated topical administration on the eye.Arzneimittelforschung1999; 49: 234–9.
9.
HejkalT.W.CamrasC.B.. Prostaglandin analogs in the treatment of glaucoma.Semin Ophthalmol1999; 14: 114–23.
10.
SagaraT.GatonD.D.LindseyJ.D.GabeltB.T.KaufmanP.L.WeinrebR.N.. Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway.Arch Ophthalmol1999; 117: 794–801.
11.
OcklindA.. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections.Exp Eye Res1998; 67: 179–91.
12.
HassardA.TingeyD.P.CargillD.MotolkoM.. The intraocular pressure lowering effect of latanoprost varies with anterior segment structures.Invest Ophthalmol Vis Sci, 2001; 42: A2248.
13.
MartinL.. Clinical experience with latanoprost: a retrospective study of 153 patients.Acta Ophthalmol1999; 77: 336–9.
14.
CamrasC.B.AlmA.WatsonP.StjernschantzJ.. Latanoprost: a prostaglandin analog for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups.Ophthalmology1996; 103: 1916–24.
15.
SuzukiM.MishimaH.K.MasudaK.AraieM.KitazawaY.AzumaI.. Efficacy and safety of latanoprost eye drops for glaucoma treatment: A 1-year study in Japan.Jpn J Ophthalmol2000; 44: 33–8.
16.
WatsonP.G.. Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group.Ophthalmology1998; 105: 82–7.
17.
AlmA.WidengardI.. Latanoprost: experience of 2-year treatment in Scandinavia.Acta Ophthalmol2000; 78: 71–6.
18.
StewartW.C.SharpeE.D.DayD.G.Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta- adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.J Ocul Pharmacol Ther2000; 16–3: 251–9.
19.
ShinD.H.McCrackenM.S.BendelR.E.The additive effect of latanoprost to maximum-tolerated medications with low-dose, highdose, or no pilocarpine therapy.Ophthalmology1999; 106–2: 386–90.
20.
KragS.AndersenH.B.SorensenT.. Circadian intraocular pressure variation with beta-blockers.Acta Ophtalmol1999; 77: 500–3.
21.
RaczP.RuzsonyiM.R.NagyZ.T.GaygiZ.BitoL.Z.. Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol.Arch Ophthalmol1996; 114: 268–73.
22.
OrzalesiN.RossettiL.InvernizziT.BottoliA.AutelitanoA.. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.Invest Ophthalmol Vis Sci2000; 41: 2566–73.
23.
KuwayamaY.ItohN.KanoK.Comparison of timolol and latanoprost in diurnal variation of hypotensive effect.Invest Ophthalmol Vis Sci2001; 42: A4396.
24.
StewartW.C.DayD.G.SharpeE.D.DubinerH.B.HolmesK.T.StewartJ.A.. Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost.Am J Ophthalmol1999; 128–6: 692–6.
25.
DiestelhorstM.AlmegardB.. Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma.Graefes Arch Clin Exp Ophthalmol1998; 236–8: 577–81.
26.
PfeifferN.YannoulisN.MertzB.CirkelC.KapikB.. The unoprostone Study Group. Efficacy and safety of unoprostone isopropyl 0.15% and latanoprost 0.005% in adjunctive therapy to timolol maleate 0.5% in patients with primary open-angle glaucoma or ocular hypertension.Invest Ophthalmol Vis Sci2001; 42: A4398.
27.
SusannaR.Jr.NicolelaM.T.OgaE.. Additive effect of latanoprost to the combination of timolol and dorzolamide.J Glaucoma2000; 9: 183–6.
28.
SimmonsS.T.SamuelsonT.W.. Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. Alphagan/Xalatan Study Group.Clin Ther2000; 22: 388–99.
29.
VetrugnoM.CantatoreF.GiganteG.CardiaL.. Latanoprost 0.005% in POAG: Effects on IOP and ocular blood flow.Acta Ophthalmol1998; 227(Suppl): S40–1.
30.
SponselW.E.ParisG.TrigoY.Latanoprost and brimonidine: Therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy.Am J Ophthalmol2002; 133: 11–8.
31.
NicolelaM.T.BuckleyA.R.WalmanB.E.DranceS.M.. A comparative study of the effects of timolol and latanoprost on blood flow velocity of the retrobulbar vessels.Am J Ophthalmol1996; 122: 784–9.
32.
HedmanK.AlmA.. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol.Eur J Ophthalmol2000; 10: 95–104.
33.
O'DonoghueE.P.. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study. Ireland Latanoprost Study Group.Br J Ophthalmol2000; 84: 579–82.
34.
Spiegel D, European Latanoprost Study Group.A comparison of the safety and efficacy of latanoprost (Xalatan®) versus the fixed combination of dorzolamide and timolol (Cosopt®) in patients with open angle glaucoma.Invest Ophthalmol Vis Sci2001; 42: A4414.
35.
DuBosarU.. Latanoprost once daily significantly more effective than brimonidine twice daily.Ocular Surgery News2000, 80.
36.
StewartW.C.DayD.G.StewartJ.A.HolesK.T.LeechJ.N.RowanC.T.SchwartzG.F.. Therapeutic success of latanoprost 0.005% compared tp brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension.J Ocul Pharmacol Ther2000; 16: 557–63.
37.
SusannaR.GiampaniJ.BorgesA.S.VessaniR.M.JordaoM.L.S.. A double masked, randomized clinical trial comparing with unoprostone in patients with open-angle glaucoma or ocular hypertension.Ophthalmology2001, 108: 259–63.
38.
YamamotoT.KitazawaY.. Iris color change developed after topical isopropyl unoprostone treatment.J Glaucoma1997; 6: 430–2.
39.
EisenbergD.L.CamrasC.B.. A preliminary risk-benefit assessment of latanoprost and unoprostone in open-angle glaucoma and ocular hypertension.Drug Saf1999; 20: 505–14.
40.
YipL.W.AungT.ChewP.T.K.Additive effect of unoprostone and latanprost in patients with elevated intraocular pressure.Invest Ophthalmol Vis Sci2001; 42: A2257.
41.
KiuchiY.FukuiK.OhnishiT.HayashidaY.IchiroI.. Additive ocular hypotensive effect of latanoprost and unoprostone in patients with open angle glaucoma.Invest Ophthalmol Vis Sci2001; 42: A4394.
42.
NetlandP.A.LandryT.SilverL.H.IOP lowering efficacy and safety of travoprost compared to latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.Invest Ophthalmol Vis Sci2001; 42: A2984.
43.
HigginbothamE.J.. The expanding field of prostaglandin analogs.Review of Ophthalmology2001; 8: 117–21.
44.
BucciM.G.. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: A randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group.J Glaucoma1999; 8–1: 24–30.
45.
NordmannJ.P.SoderstromM.RoulandJ.F.MalecazeF.. Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish Latanoprost Study Group.Br J Ophthalmol2000; 84: 181–5.
46.
EmmerichK.H.. A comparison of latanoprost monotherapy to dorzolamide combined with timolol in glaucoma and ocular hypertension patients.New Orleans: Am Acad Ophthalmology, 1998.
47.
Fuchs M, The Latanoprost Drug Observation Group.Latanoprost: Efficacy and safety in a 6 months observational study.Invest Ophthalmol Vis Sci2001; 42: A2242.
48.
KentA.R.VromanD.T.ThomasT.J.HebertR.L.CrossonC.E.. Interaction of pilocarpine with latanoprost in patients with glaucoma and ocular hypertension.J Glaucoma1999; 8: 257–62.
49.
RuloA.H.GreveE.L.GeijssenH.C.HoyngP.F.J.. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal pressure glaucoma.Ophthalmology1996; 103: 1276–82.
50.
TamadaY.TaniguchiT.MuraseH.YamamotoT.KitazawaY.. Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma.J Ocul Pharmacol Ther2001; 17: 19–25.
51.
GreveE.L.RuloA.H.DranceS.M.CrichtonA.C.MillsR.P.HoyngP.F.. Reduced intraocular pressure and increased ocular perfusion pressure in normal tension glaucoma: a review of short-term studies with three dose regimens of latanoprost treatment.Surv Ophthalmol1997; 41(Suppl): S89–92.
52.
DranceS.M.CrichtonA.MillsR.W.. Ocular perfusion pressure in normal tension glaucoma patients after latanoprost or timolol treatment.Chicago: Am Acad Ophthalmology, 1996.
53.
DranceS.M.CrichtonA.MillsR.P.. Comparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion pressure in patients with normal-tension glaucoma.Am J Ophthalmol1998; 125: 585–92.
54.
GarzoziH.HarrisA.KagemannL.Comparison of dorzolamide and latanoprost in normal-tension glaucoma: Effects on IOP and retinal hemodynamics.Invest Ophthalmol Vis Sci2001; 42: A125.
55.
AungT.WongH.A.T.YipC.C.LeongJ.Y.ChanY.H.ChewP.T.. Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: A preliminary study.Ophthalmology2000; 107: 1178–83.
56.
HungP.T.HsiehJ.W.ChenY.F.WeiT.. Efficacy of latanoprost as an adjunct to medical therapy for residual angle-closure glaucoma after iridectomy.J Ocul Pharmacol Ther2000; 16–1: 43–7.
57.
MastropasquaL.CarpinetoP.CiancagliniM.GallengaP.E.. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma.Ophthalmology1999; 106: 550–5.
58.
SchererW.J.MielkeD.L.TidwellP.E.HauberF.A.. Effect of latanoprost on intraocular pressure following cataract extraction (see comments).J Cataract Refract Surg1998; 24: 964–7.
59.
LaiJ.S.ChuaJ.K.LeungA.T.LamD.S.. Latanoprost versus timolol gel to prevent ocular hypertension after phacoemulsification and intraocular lens implantation.J Cataract Refract Surg2000; 26: 386–91.
60.
RainerG.MenapaceR.SchmettererK.FindlO.GeorgopoulosM.VassC.. Effect of dorzolamide and latanoprost on intraocular pressure after small incision cataract surgery.J Cataract Refract Surg1999; 25: 1624–9.
61.
SchererW.J.HauberF.A.. Effect of latanoprost on intraocular pressure in steroid-induced glaucoma.J Glaucoma2000; 9: 179–82.
62.
GaddieI.B.BennettD.W.. Cystoid macular edema associated with the use of latanoprost.J Am Optom Assoc1998; 69: 122–8.
63.
FechtnerR.D.KhouriA.S.ZimmermanT.J.Anterior uveitis associated with latanoprost.Am J Ophthalmol1998; 126: 37–41.
64.
EnyediL.B.FreedmanS.F.BuckleyE.G.. The effectiveness of latanoprost for the treatment of paediatric glaucoma.J AAPOS1999; 3: 33–9.
65.
MerttsM.GarfieldS.TanemotoK.TomarevS.I.. Identification of the region in the N-terminal domain responsible for the cytoplasmic localization of Myoc/Tigr and its association with microtubules.Lab Invest1999; 79: 1237–45.
66.
AltunaJ.C.GreenfieldD.S.WandM.Latanoprost in glaucoma associated with Sturge-Weber syndrome: Benefits and side-effects.J Glaucoma1999; 8: 199–203.
67.
WarwarR.E.BullockJ.D.BallalD.. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients.Ophthalmology1998; 105: 263–8.
68.
JohnstoneM.A.. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost.Am J Ophthalmol1997; 124: 544–7.
69.
CamrasC.B.NeelyD.G.WeissE.L.. Latanoprost-induced iris color darkening: A case report with long- term follow-up.J Glaucoma2000; 9: 95–8.
70.
DutkiewiczR.AlbertD.M.LevinL.A.. Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines.Exp Eye Res2000; 70: 563–9.
SmithS.L.PruittC.A.SineC.S.HudginsA.C.StewartW.C.. Latanoprost 0.005% and anterior segment uveitis.Acta Ophthalmol1999; 77: 668–72.
73.
SaccàS.PascottoA.SiniscalchiC.RolandoM.. Ocular complications of latanoprost in uveitic glaucoma, three case reports.J Ocul Pharmacol Ther2001; 17: 107–13.
74.
ArdjomandN.AignerR.El-ShabrawiY.. The role of latanoprost in intraocular inflammation revisited.Invest Ophthalmol Vis Sci2001; 42: A3980.
75.
SchumerR.A.CamrasC.B.MandahlA.K.. Latanoprost and cystoid macular edema: is there a causal relation?Curr Opin Ophthalmol2000; 11–2: 94–100.
76.
MiyakeK.OtaI.IbarakiN.Enhanced disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema by topical timolol and its preservative in early postoperative pseudophakia.Arch Ophthalmol2001; 119: 387–94.
77.
MiyakeK.OtaI.MaekuboK.IchihashiS.MiyakeS.. Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias.Arch Ophthalmol1999; 117: 34–40.
78.
ThygesenJ.AaenK.TheodorsenF.KessingS.V.PrauseJ.U.. Short-term effect of latanoprost and timolol eye drops on tear fluid and the ocular surface in patients with primary open-angle glaucoma and ocular hypertension.Acta Ophthalmol Scand2000; 78: 37–44.
79.
WandM.GilbertCM.LiesegangT.J.. Latanoprost and herpes simplex keratitis.Am J Ophthalmol1999; 127: 602–4.
VeyracG.ChiffoleauA.CellerinL.LarousseC.BourinM.. Latanoprost (Xalatan) and a systemic respiratory effect? Apropos of a case (letter). Latanoprost (Xalatan) et effet systemique respiratoire? A propos d'un cas.Therapie1999; 54: 494–6.
83.
LindenC.NuijaE.AlmA.. Effects on IOP restoration and blood-aqueous barrier after long-term treatment with latanoprost in open angle glaucoma and ocular hypertension.Br J Ophthalmol1997; 81: 370–2.
84.
AsraniS.ZeimerR.WilenskyJ.GiesserD.VitaleS.LindenmuthK.. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma.J Glaucoma2000; 9: 134–42.
85.
FlammerJ.RobertY.GloorB.. Influence of pindolol and timolol treatment on the visual fields of glaucoma patients.J Ocul Pharmacol1986; 2: 305–11.
86.
MessmerC.FlammerJ.StumpfigD.. Influence of betaxolol and timolol on the visual fields of patients with glaucoma.Am J Ophthalmol1991; 15: 678–81.
87.
KaiserH.J.FlammerJ.StumpfigD.HendricksonP.. Longterm visual field follow-up of glaucoma patients treated with beta-blockers.Surv Ophthalmol1994; 38–156–9: 160.
88.
FlammerJ.KitazawaY.BonomiL.Influence of carteolol and timolol on IOP and visual fields in glaucoma: a multi-center, doublemasked, prospective study.Eur J Ophthalmol1992; 2: 169–74.
89.
MermoudA.. Modern anti-glaucoma drugs and their secondary effects. Les médicaments antiglaucomateux modernes et leurs effets secondaires.Rev Med Suisse Romande1998; 118: 937–40.
